Genetic polymorphisms in drug metabolizing enzymes: Impact on treatment with β-blockers;Genpolymorphismen in arzneimittel-abbauenden enzymen: Bedeutung für die therapie mit β-blockern

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 15, 2004, Pages 831-835

  Wuttke, H ^a   Rau, T ^a   Eschenhagen, T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CYTOCHROME P450 2D6; METOPROLOL; NEBIVOLOL;

DNA POLYMORPHISM; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME METABOLISM; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALLELES; ATENOLOL; BENZOPYRANS; BIOTRANSFORMATION; BISOPROLOL; CARBAZOLES; CLINICAL TRIALS; CYTOCHROME P-450 CYP2D6; ETHANOLAMINES; FEMALE; GENOTYPE; HUMANS; MALE; METOPROLOL; MUTATION; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PROPANOLAMINES; RISK FACTORS; TIME FACTORS;

EID: 1942532957     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-823030     Document Type: Review

References (40)

1. Abrahamsson B, Lücker P, Olofsson B et al. The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. J Clin Pharmacol 1990; 30: S46-S54
2. BERLIN-CHEMIE AG. Fachinformation Nebilet®; 2003
3. Cheymol G, Woestenborghs R, Snoeck E et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997; 51: 493-498
4. Clark DW, Morgan AK, Waal-Manning H. Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 1984; 18: 965-967
5. Collette D, Thürmann PA. Unerwünschte Arzneimittelwirkungen. Erbliche Unterschiede im Arzneistoffmetabolismus. Dtsch Med Wochenschr 2002; 127: 1025-1028
6. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516-520
7. Deroubaix X, Lins RL, Lens S et al. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers. Int J Clin Pharmacol Ther 1996; 34: 61-70
8. Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nat Med 2001; 7: 285-287
9. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-187
10. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549
11. Gottlieb SS, Fisher ML, Kjekshus J et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HP). Circulation 2002; 105: 1182-1188
12. Graff DW, Williamson KM, Pieper JA et al. Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. J Clin Pharmacol 2001; 41: 97-106
13. Griese EU, Zanger UM, Brudermanns U et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26
14. Horikiri Y, Suzuki T, Mizobe M. Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci 1998; 63: 1097-1108
15. Human Allele Nomenclature Committee. Home Page of the Human Cytochrome P450 (CYP) http://www.imm.ki.se/CYPalleles/, 2004
16. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 89-104
17. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs 2003; 63: 1697-1741
18. Komajda M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-474
19. Lacourciere Y, Poirier L, Lefebvre J, Archambault F, Cleroux J. Comparative assessment of antihypertensive efficacy of DL-nebivolol and D-nebivolol in patients with confirmed mild to moderate hypertension. J Cardiovasc Pharmacol 1995; 25: 619-624
20. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-1294
21. Leineweber K, Büscher R, Brück H, Brodde OE. beta-Adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 1-22
22. Lemmer B. Betarezeptorenblocker. Berlin Heidelberg: Springer-Verlag, In: Schwabe U, Paffrath D, editors. Arzneiverordnungsreport 2001. 2001: 287-296
23. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307: 1558-1560
24. Lennard MS, Tucker GT, Silas JH, Woods HF. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986; 16: 435-447
25. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 1986; 8: S16-20
26. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003; 93: 896-906
27. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977; 2: 584-586
28. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633-651
29. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-1671
30. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10: 577-581
31. Rau T, Heide R, Bergmann K et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12: 465-472
32. Roden DM. Cardiovascular pharmacogenomics. Circulation 2003; 108: 3071-3074
33. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295
34. Siddoway LA, Thompson KA, McAllister CB et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785-791
35. Van Rooy P, De Crée J. Haemodynamic effects of nebivolol in poor and extensive metabolisers. Drug Investig 1991; 3: 161-163
36. Wadworth AN, Murdoch D, Brogden RN. Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991; 42: 468-510
37. Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol 1987; 24: 213-220
38. Wuttke H, Rau T, Heide R et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429-437
39. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 23-37
40. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995; 57: 518-524